Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06952803CT.gov A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | — | Recruiting | — | — | — |
NCT07005154CT.gov A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | — | Recruiting | — | — | — |
NCT06768255CT.gov Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC | — | Not Yet Recruiting | — | — | — |
NCT06652607CT.gov PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT05288166CT.gov A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | — | Active Not Recruiting | — | — | — |
NCT04736108CT.gov Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | — | Unknown | — | — | — |
NCT05406999CT.gov Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT02441894CT.gov Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer | — | Completed | — | — | — |
NCT01485861CT.gov Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | — | Completed | — | — | — |
NCT00751205CT.gov Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00498797CT.gov E3-Hormone Refractory Prostrate Cancer Taxotere Combination | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
NCT00124566CT.gov Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisolone (this asset) | AstraZeneca | Approved | BB · 65 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Prednisolone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infantile Spasms | — | P4 | BBB · 79 |
| Non-Hodgkin Lymphoma | — | P3 | BBB · 74 |
| Lymphoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisolone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisolone-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →